225 related articles for article (PubMed ID: 38517652)
1. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.
Dai Q; Zhang Y; Liu Q; Zhang C
Clin Rheumatol; 2024 May; 43(5):1605-1613. PubMed ID: 38517652
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
3. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Asahina A; Etoh T; Igarashi A; Imafuku S; Saeki H; Shibasaki Y; Tomochika Y; Toyoizumi S; Nagaoka M; Ohtsuki M;
J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.
Eder L; Gladman DD; Mease P; Pollock RA; Luna R; Aydin SZ; Ogdie A; Polachek A; Gruben D; Cadatal MJ; Kinch C; Strand V
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36958766
[TBL] [Abstract][Full Text] [Related]
5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
Merola JF; Papp KA; Nash P; Gratacós J; Boehncke WH; Thaçi D; Graham D; Hsu MA; Wang C; Wu J; Young P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2809-2820. PubMed ID: 32271970
[TBL] [Abstract][Full Text] [Related]
8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.
Leng X; Lin W; Liu S; Kanik K; Wang C; Wan W; Jiang Z; Liu Y; Liu S; Zhang Z; Zhang Z; Xu J; Tan W; Hu J; Li J; Liu J; Gunay LM; Dina O; Kinch C; Zeng X
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36720560
[TBL] [Abstract][Full Text] [Related]
10. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
Giles JT; Ogdie A; Gomez Reino JJ; Helliwell P; Germino R; Stockert L; Young P; Joseph W; Mundayat R; Graham D; Ritchlin C
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33452181
[TBL] [Abstract][Full Text] [Related]
11. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Yang F; Lu C; Wang Y; Liu H; Leng X; Zeng X
Clin Rheumatol; 2023 Jun; 42(6):1593-1605. PubMed ID: 36763226
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
Mease PJ; Orbai AM; FitzGerald O; Bedaiwi M; Dona L Fleishaker ; Mundayat R; Young P; Helliwell PS
Arthritis Res Ther; 2023 Aug; 25(1):153. PubMed ID: 37608391
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.
Tian F; Chen Z; Xu T
J Int Med Res; 2019 Jun; 47(6):2342-2350. PubMed ID: 31096817
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Ighani A; Georgakopoulos JR; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
[TBL] [Abstract][Full Text] [Related]
17. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Zhang L; Guo L; Wang L; Jiang X
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
[TBL] [Abstract][Full Text] [Related]
19. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Su QY; Zhou HN; Xia GM; Zhang RY; Tian HY; Su C; Liu YX; Zhang HY; Cheng T; Huo YH; Li Q; Zhang SX
Rheumatol Ther; 2024 Apr; 11(2):227-237. PubMed ID: 38302785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]